Clinical Validation of Automated and Rapid mariPOC SARS-CoV-2 Antigen Test
==========================================================================

* Juha M. Koskinen
* Petri Antikainen
* Kristina Hotakainen
* Anu Haveri
* Niina Ikonen
* Carita Savolainen-Kopra
* Janne O. Koskinen

## ABSTRACT

Novel SARS coronavirus causing COVID-19 was recognized in late 2019. Diagnostics was quickly ramped up worldwide based on the detection of viral RNA. Based on the scientific knowledge for pre-existing coronaviruses, it was expected that the RNA of this novel coronavirus will be detected at significant rates from symptomatic and asymptomatic individuals due to existence of non-infectious RNA. To increase the efficacy of diagnostics, surveillance, screening and pandemic control, rapid methods, such as antigen tests, are needed for decentralized testing and to assess infectiousness. The objectives were to verify analytical sensitivity and specificity, and assess the clinical sensitivity, specificity and usability of a novel automated mariPOC SARS-CoV-2 test based on sophisticated optical laser technology detecting viral structure proteins. Analytical performance was verified using bacterial and viral preparations. Clinical performance of the test was evaluated against qRT-PCR in a retrospective study with nasopharyngeal swab specimens (N=211) collected from symptomatic patients suspected of acute SARS-CoV-2 infections. Sensitivity and specificity of the mariPOC test were 92.3% (12/13) and 100.0% (198/198), respectively. The test’s limit of detection was 22 PFU/test and it had no cross-reactions with the tested respiratory microbes. Our study shows that the mariPOC can detect infectious individuals already in 20 minutes while clinical sensitivity close to qRT-PCR is achieved in two hours or less. The test targets conserved epitopes of SARS-CoV-2 nucleoprotein, making it robust against strain variations. The new test is a promising and versatile tool for syndromic testing of symptomatic cases and for high capacity infection control screening.

KEYWORDS
*   COVID-19
*   SARS-CoV-2
*   antigen detection
*   mariPOC
*   PCR
*   infectious
*   screening
*   infection control
*   pandemic

Emerging pandemic coronavirus (CoV) was recognized in Wuhan, China, in late 2019. The virus, isolated from patients mentioned to be pneumonic, was quickly sequenced to share 79.6% full length genome similarity with the Severe Acute Respiratory Syndrome virus (SARS-CoV-1) and 91.2% similarity between its nucleocapsid (N) proteins (1). The novel SARS-CoV-2, causing COVID-19, was identified to be circulating in horseshoe bats for decades similarly to SARS-CoV-1 (2). Diagnostic nucleic acid amplification tests (NAAT), mostly quantitative real-time polymerase chain reaction (qRT-PCR), were quickly developed worldwide, based on protocol provided for World Health Organization (3). Diagnostic qRT-PCR capacities were ramped up quickly in central laboratories because such tests are fast to develop for new targets.Most often, the new qRT-PCR tests were adopted for clinical diagnostics with minimal verification and validation against other diagnostic test methods, such as viral culture and serology.

For the seasonal coronaviruses, the interpretation of gene positivity in clinical specimens has been challenging since the viral RNA is detected at similar rates and qRT-PCR cycle threshold (Ct) values from symptomatic and asymptomatic individuals. The viral RNA is also co-detected with genomes of other respiratory viruses (4-7). This is also the case for the SARS-CoV-2 (8, 9). Moreover, recent scientific evidence indicates that qRT-PCR positivity has poor correlation for assessment of SARS-CoV-2 infectiousness (10-16). Whereas, Pekosz et al. (2020) showed that the detection of N-protein by an antigen test correlates with SARS-CoV-2 viral culture more accurately than qRT-PCR (13). Already half a decade ago Inagaki et al. (2016) unequivocally concluded for influenza that, “PCR…is not an appropriate method for indicating infectivity” and “the antigen-detection test estimated the infectious period with comparable if not better accuracy with culture” (17). In the case of COVID-19 diagnostics, the fact that viral RNA persistence can be detected without viable virus for months, has been a known clinical challenge, as diagnostics relied in the beginning of the pandemic solely on NAAT detection (18), the efficacy of which is in ruling out positivity.

The expression of N-protein, which is the key pathogenicity factor of coronaviruses (19), is essential for the coronavirus replication and transcription of the viral RNA (20, 21). Without the accumulation of the N-protein, the coronaviral mRNA is degraded by the nonsense-mediated decay (NMD) pathway of eukaryotic cells (19). Alexandersen at al. (2020) concluded that the detection of RNA is not an indicator of actively replicating SARS-CoV-2. Their data suggests that virion and subgenomic RNAs are stable in cellular double-membrane vesicles and, therefore, can be detected long after the acute infection (22).

Shortly after viral exposure, viral concentration is low and qRT-PCR Ct values are high. When the virus starts replication, it happens fast. In a cell model, extensive coronavirus RNA transcription has occurred in 6 to 8 hours after the infection (23). In addition, NAATs being prone for reporting clinically insignificant findings (analytically the detection may be correct, there is viral RNA in the sample) they are prone to contaminations. A study of SARS-CoV-2 primer-probe sets from four major European suppliers found a significant level of contamination from the reagents. False positives as low as qRT-PCR Ct 17 were obtained (24). Low levels of SARS-CoV-2 RNA contamination has also been found from surfaces and air in rooms where mildly ill individuals were isolated without notable viable virus (25, 26). It has also been shown that environmental contamination may yield in positive test results in PCR among individuals sampled in the same area where intranasal influenza vaccine dosing was done (27). These data suggests that individuals having presence near symptomatic patients can be contaminated by RNA without being infected with viable virus. Thus, methods detecting the viral RNA by amplification are prone for clinically insignificant positive results, especially when significant part of the population has been infected recently. The fact that a positive NAAT result is not a reliable biomarker of active infection or COVID-19, is a true challenge for clinicians and decision making for quarantine. It is not only that a missed necessary quarantine has health and epidemic costs but also that a falsely imposed quarantine has social and financial consequences (28).

The different performance requirements of diagnostic, surveillance and screening testing have been recently discussed by Mina and Andersen (2020). There is a need for both super sensitive PCR based tests and rapid and appropriately sensitive antigen tests to fight the COVID-19 pandemic (29). The use of the two methodologies should supplement one another in clinical practice and pandemic fight.

In the present study, we analytically and clinically validated the performance of a novel mariPOC SARS-CoV-2 test (ArcDia International Ltd, Finland), intended for rapid and automated detection of viral acute phase proteins when there is a clinical suspicion of acute COVID-19. Monoclonal antibodies of the test are designed to target a conserved epitope in the N-protein, which is the most abundant protein in coronaviruses. We have previously shown that the presence of coronavirus OC43 N-protein in the nasopharynx correlates with the respiratory tract infection symptoms (30). It has been shown that clinical presentations of seasonal coronavirus OC43 infections can be similar to those of coronaviruses that are considered as severe viruses (SARS and MERS) (31).

The mariPOC is an automated platform for the rapid multianalyte testing of acute infectious diseases. It is based on a separation-free two-photon excitation assay technique (32, 33). Subsequently to nasopharyngeal sampling, the mariPOC test’s operational steps are: combining the swab with the sample buffer from a bottle-top dispenser, vortexing the sample tube to release the sample from the swab (Figure 1), followed by automated analysis and objective fluorescent result read out. The analysis is performed by an automated analyzer with sophisticated autoverification functions, and the result can be transferred automatically to the laboratory information system or as anonymized epidemiological data (34) into mariCloud™ service. The hands-on time is one minute per sample, and the analyzer works in continuous-feed and walk-away mode. The mariPOC SARS-CoV-2 test is available as a single pathogen test and as part of syndromic multianalyte tests covering, among others, influenza viruses. The throughput of one mariPOC analyzer can be up to 300 single analyte tests or 100 multianalyte tests in 24 hours. The results are reported in two phases, highly infectious cases in twenty minutes and low positive and negative cases in two hours or less, depending on the test configuration.

![Figure 1.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2021/02/11/2021.02.08.21250086/F1.medium.gif)

[Figure 1.](http://medrxiv.org/content/early/2021/02/11/2021.02.08.21250086/F1)

Figure 1. 
Sample pretreatment in the mariPOC SARS-CoV-2 test before placing the sample tube into the analyzer for automated analysis and subsequent test result read out objectively as positive or negative.

## MATERIALS AND METHODS

### Analytical sensitivity

Nasopharyngeal swab specimens from asymptomatic individuals were suspended into mariPOC RTI sample buffer into volume corresponding to 1.3 mL per swab. This pooled clinical sample matrix was spiked with 75 µL of UV-inactivated SARS-CoV-2 culture supernatant (2 × 106 PFU/mL, Ct 17, University of Helsinki, Finland) per swab in different concentrations (plaque-forming unit). The samples were analyzed with the mariPOC SARS-CoV-2 test following the manufacturer’s instructions. Preparation of the virus is described in the referenced study (35). Limit of Detection (LoD) was determined as the lowest concentration giving at least 19 positives out of 20 replicates (≥95% positivity).

### Cross-reactivity

Analytical specificity of the mariPOC SARS-CoV-2 test was studied by challenging the test against relevant microbes commonly found in the nasal cavity (supplemental material). Briefly, the microbe stocks were suspended in high concentration in the mariPOC RTI sample buffer and analyzed with the mariPOC SARS-CoV-2 test.

### Verification

For preliminary validation of the mariPOC SARS-CoV-2 test forty five positive pseudonymized specimens with known qRT-PCR Ct values (16 to 34) from the frozen nasopharyngeal swab specimen library of Finnish Institute of Health and Welfare, Helsinki, Finland, in undefined transport mediums, were tested. The qRT-PCR protocol was an in-house method based on the primers and probes by Corman et al. (2020) (3). The cohort consisted mostly of symptomatic, but in part also of asymptomatic subjects, while the detailed information for each subject was not available for this study. The specimens were in either reddish (N=22) or colorless (N=23) solutions. The samples were diluted into the mariPOC RTI sample buffer in one-to-one (1:1) ratio and analyzed with the mariPOC test. The positivity rate of the mariPOC test was compared to different qRT-PCR Ct value categories.

### Clinical validation

Nasopharyngeal swab specimens (N=211) were collected from patients visiting primary healthcare COVID-19 drive-in stations of Mehiläinen Oy in Helsinki capital area of Finland from March to April 2020. The enrollment criteria were respiratory infection symptoms and clinician’s suspicion of COVID-19, the official criteria for COVID-19-testing in Finland and at the clinical study sites at the time of the study. The samples were taken with a flocked swab from the nasopharynx (8 to 12 cm deep for adults and 4 to 8 cm deep for children) by rotating the swab in nasopharyngeal cavity for 10 seconds.

Two consecutive specimens were collected from 127 patients giving an oral consent to participate in the study. The specimens were collected during an internal laboratory method validation study, which does not require external ethical review board permission and was not linked with recruitment or treatment of patients (36). The study was approved by the responsible chief physician of Mehiläinen Oy. The specimen for standard of care testing was collected first. These specimens were analyzed after RNA extraction with Allplex™ 2019-nCoV RT-PCR assay (Seegene Inc., Republic of Korea) at Seoul Clinical laboratories (Republic of Korea). Allplex™ 2019-nCoV RT-PCR assay detects E, N and RdRP genes (37). The second swab specimen was kept in a dry tube at +4 °C for a maximum of 8 hours and stored frozen until analysis with the mariPOC SARS-CoV-2 test.

For 84 patients, one specimen was collected. These swabs were suspended into saline (0.5−1 mL) and analyzed with Amplidiag COVID-19 qRT-PCR assay including RNA extraction (Mobidiag Ltd, Finland) at Vita Laboratorio Ltd (Finland). Amplidiag COVID-19 qRT-PCR assay detects N and ORF1ab genes (38). The leftover saline specimens were stored frozen until analysis with the mariPOC SARS-CoV-2 test.

The dry swab specimens and leftover saline samples were analyzed retrospectively with the mariPOC test by two operators following the manufacturer’s instructions. Briefly, dry swabs were suspended into 1.3 mL of the mariPOC RTI sample buffer and the leftover saline samples (range 0.1−0.65 mL) were diluted with RTI sample buffer to a final volume of 1.3 mL.

When a discrepant result between the mariPOC and comparator RT-PCR was obtained, the swab samples taken for the mariPOC were confirmatory tested at the Department of Clinical Microbiology, Turku University Hospital (Finland) with an in-house reference qRT-PCR detecting E, N and RdRP genes (3).

## RESULTS

### Analytical sensitivity

LoD of the mariPOC SARS-CoV-2 test was 22 PFU/test in 20 µL reaction volume when all twenty replicates gave a positive test result. In 50% tissue culture infective dose units, this corresponds to 40 TCID50/test (39). The calculated LoD in qPCR Ct units was 28.

### Cross-reactivity

The mariPOC test had no cross-reactions. The mariPOC test did not cross-react with seasonal coronaviruses OC43, 229E, or NL63, but it detected the recombinant N-protein of SARS-CoV-1. Detailed information is shown in supplemental material.

### Verification study

Overall, 21 out of 45 verification samples were positive with the mariPOC (Figure 2). The test showed 90% positivity rate compared to qRT-PCR for Ct values 25 and lower (Table 1). Above the Ct value 25, the positivity rate of the mariPOC declined as typical for an antigen test.

View this table:
[Table 1.](http://medrxiv.org/content/early/2021/02/11/2021.02.08.21250086/T1)

Table 1. 
Cumulative positivity rates of viral culture (three studies) and mariPOC (verification study data) compared to qRT-PCR.(10, 12, 14)

![Figure 2.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2021/02/11/2021.02.08.21250086/F2.medium.gif)

[Figure 2.](http://medrxiv.org/content/early/2021/02/11/2021.02.08.21250086/F2)

Figure 2. 
Ct values of qRT-PCR for mariPOC test positive (green) and negative (red) samples in the verification sample cohort. Dotted and dashed line at Ct 25 and 29, respectively.

### Clinical validation

Prevalence of SARS-CoV-2 in the study cohort was 6%, which is well in alignment with the prevalence during the study time in the geographical area (5%). Considering the confirmatory qRT-PCR results, the mariPOC SARS-CoV-2 test and the primary comparator RT-PCR detected 12 and 13 true positive samples, respectively. In comparison to the PCR testing, sensitivity and specificity of the mariPOC test were 92.3% (12/13) and 100.0% (198/198), respectively (Table 2). In the preliminary result reporting phase at 20 minutes, the mariPOC test detected 75.0% (9/12) of the positive samples, compared to the final reporting phase in 2 hours, and the specificity was 100.0% (198/198). Analytical specificity of the qRT-PCR was 99.5% (197/198). Detailed description of positive samples is shown in supplemental material.

View this table:
[Table 2.](http://medrxiv.org/content/early/2021/02/11/2021.02.08.21250086/T2)

Table 2. 
Performance of mariPOC SARS-CoV-2 test (validation study data) when compared with the qRT-PCR methods.

## DISCUSSION

When setting up a diagnostic process or choosing a diagnostic method, one should carefully consider, to start with, whether the disease, clinical condition and use case, require high sensitivity for ruling out or high specificity for ruling in. There is a need for both in fighting the COVID-19 pandemic. In general, analytically highly sensitive testing, such as PCR testing, is good at ruling out a disease (e.g. keeping a ward clean) while highly specific testing, such as antigen testing, is good at ruling in a disease (e.g. acute infection diagnostics and assessing infectiousness). Because of rapidity and lesser logistic challenges compared to central lab testing, antigen testing is particularly good in surveillance, field-testing, screening of masses, cohorting of inpatients, acute disease diagnostics, and in assessing the infectiousness of individuals (13, 40). Especially when disease prevalence is low, clinical specificity of the screening and diagnostic testing should be emphasized to keep unnecessary quarantines and economic damages at minimum while still allowing sufficient enough infection control (29).

According to scientific data, to effectively prevent spread of the disease, pandemic control should prioritize accessibility, frequency of testing, and rapid sample-to-answer time over test sensitivity (38, 41, 42). Viral load and probability to infect others is highest just prior to onset of symptoms and during the symptomatic phase (43).

We describe here analytical and clinical verification and validation of mariPOC SARS-CoV-2 test sensitivity and specificity. Determination of LoD was performed with UV-inactivated viral culture supernatant and showed that only 22 PFU (40 TCID50) per test was needed for positive test result with ≥95% confidence. Based on high identity (89.1%) between SARS-CoV-1 (Uniprot entry, P59595) and SARS-CoV-2 (UniProt entry, P0DTC9) nucleocapsid protein sequences, and obtaining positive result for purified SARS-CoV-1 nucleocapsid protein in cross-reactivity testing (Table S1 in the supplemental material), it is highly likely that the mariPOC test detects also the SARS-CoV-1 virus itself. Cross-reactions were not observed. A minor limitation of the study is that cross-reactivity for MERS coronavirus and coronavirus HKU1 were assessed using purified protein and sequence analysis (supplemental material) and not with clinical samples or cultured virus.

Our verification cohort showed 90% positivity rate for the mariPOC below qRT-PCR Ct 25 (Table 1 and Figure 2). This was an excellent result taking into account that the samples were unfavorable for the fluorescent mariPOC platform. Colorful transport media are not recommended for mariPOC testing since they elevate fluorescent signal levels (44) and unnecessarily dilute the samples, which reduces sensitivity. The obtained results were, nevertheless, similar compared to what has been reported in the literature for the correlation between SARS-CoV-2 viral culture and qRT-PCR results, as summarized in Table 1. In addition, our results are in line with at least two other N-protein detecting tests that were evaluated against RT-PCR and culture (35, 45). Several studies have shown that infectivity of SARS-CoV-2 declines rapidly in samples showing qRT-PCR Ct above 25, and viable virus is rarely isolated after 8 days from onset of the symptoms. The detection of sole viral RNA, especially at low levels without the detectable level of viral N-protein or culture positivity, is a questionable marker of acute infection and infectiousness (10-14, 16, 46-48).

In the clinical validation study, the specificity of the mariPOC SARS-CoV-2 test was high (100.0%), with high confidence (95% CI, 98.15% to 100.00%, exact Clopper-Pearson method), in analysis of clinical nasopharyngeal swab specimens as native (preferred specimen type) or in saline. The results suggest that the clinical sensitivity of the mariPOC test (92.3%) is similar to rapid RT-PCR (93.4%), (38) when symptomatic patients suspected with acute COVID-19 infection are tested within the first five days of symptoms and reasonable (here 5%) prevalence among tested samples. Recommended sample in the mariPOC test is native nasopharyngeal swab specimen suspended into 1.3 mL of the RTI sample buffer. Other specimen types may yield in lower apparent sensitivity. In the clinical validation, suspending part of the swabs first into saline prior to the addition of RTI sample buffer diluted the specimens 2 to 10 times (1 to 3 in Ct values) more than the recommended sample pretreatment. Additional dilution lowers the sensitivity compared to the recommended protocol, and could have lead to an underestimation of the test sensitivity.

Strengths of the validation study included that the specimens were collected in the early phase of the COVID-19 pandemic in Finland that minimized the detection of RNA persistence with the RT-PCR among the cohort population. In addition, this study was conducted by using the mariPOC test as instructed by the test manufacturer, while according to a recent review, three-quarters of studies evaluating SARS-CoV-2 tests did not follow the instructions given by test manufacturers (49).

Limitations of the validation study were that the patient characteristics and the number of symptomatic days before sampling were not available for the study. Another limitation was the use of two different PCRs, and low number of positive cases, which gives relatively wide confidence range for the sensitivity (95% CI, 64.0% to 99.8%). Freezing and thawing of the samples prior to mariPOC testing was also a limitation. However, if any, this could have had a negative effect on the mariPOC test sensitivity and, hence, the study at least did not overestimate the sensitivity of the mariPOC SARS-CoV-2 test.

## Conclusions

In conclusion, the mariPOC SARS-CoV-2 test is an automated, highly specific and clinically accurate test with rapid sample-to-answer time for individuals with clinical suspicion and in acute phase of an infection. The closed tube test system and the design of operational steps minimize specimen handling and possible exposure of user to infectious material. The multianalyte syndromic tests help to differentiate between SARS-CoV-2 and other viruses, such as influenza. The single analyte test provides high capacity of 300 samples a day at the point-of-care. Objective result read-out and LIS connectability minimize manual work and human errors. Our study together with other scientific data suggests that the mariPOC can detect most infectious individuals already in 20 minutes while similar clinical sensitivity than that of rapid PCR is achieved in 2 hours or less. The positivity rate of mariPOC compared to qRT-PCR Ct values in clinical samples is very high up to Ct 25, and samples up to Ct 29 can be detected (Figure 2, Supplementary table 2). This data is in good agreement with the LoD 28 in qPCR Ct values with the inactivated virus. The detection of conserved epitope in the N-protein of SARS coronaviruses with the mariPOC likely provides accurate information about infectiousness similarly to other antigen tests and viral culture and suggests ability to detect also emerging virus variants. Further studies using viral culture as comparative method and follow-up of infectiousness of patients using antigen detection are needed in order to optimize viral respiratory tract infection management.

## Supporting information

SUPPLEMENTARY MATERIAL 1 [[supplements/250086_file04.pdf]](pending:yes)

## Data Availability

Anonymised line data is available upon request.

## SUPPLEMENTAL MATERIAL

Supplemental material is available online only. SUPPLEMENTAL FILE 1, PDF file, 0.4 MB.

## FUNDING

ArcDia International Ltd contributed the study with the mariPOC test system and consumables. The study was partly supported by Business Finland, the Finnish Funding Agency for Innovation, under the project reference 35239/31/2020.

## CONFLICTS OF INTEREST

JMK, PA and JOK are employees at ArcDia International Ltd.

## AUTHOR CONTRIBUTIONS

JMK and PA: Major contributions in the development of the mariPOC test, in scientific design and execution of the studies, result analysis, scientific analysis, and writing of the manuscript.

KH: Major contributions in providing specimens for clinical validation, in scientific analysis and revising the manuscript.

AH: Major contributions in providing specimens for verification, in scientific analysis and revising the manuscript.

NI and CS-K: Major contributions in scientific analysis, and revision of the manuscript.

JOK: Major contributions in the development of the mariPOC test and in scientific design, execution, and analysis of the results, and revision of the manuscript.

## ACKNOWLEDGEMENTS

We thank Vita laboratories Ltd and Seoul Clinical Laboratory for performing RT-PCR analyses.

*   Received February 8, 2021.
*   Revision received February 8, 2021.
*   Accepted February 11, 2021.


*   © 2021, Posted by Cold Spring Harbor Laboratory

This pre-print is available under a Creative Commons License (Attribution-NoDerivs 4.0 International), CC BY-ND 4.0, as described at [http://creativecommons.org/licenses/by-nd/4.0/](http://creativecommons.org/licenses/by-nd/4.0/)

## REFERENCES

1.  1.Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W, Si H, Zhu Y, Li B, Huang C, Chen H, Chen J, Luo Y, Guo H, Jiang R, Liu M, Chen Y, Shen X, Wang X, Zheng X, Zhao K, Chen Q, Deng F, Liu L, Yan B, Zhan F, Wang Y, Xiao G, Shi Z. 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579:270–273. [https://doi.org/10.1038/s41586-020-2012-7](https://doi.org/10.1038/s41586-020-2012-7).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41586-020-2012-7&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F02%2F11%2F2021.02.08.21250086.atom) 

2.  2.Boni MF, Lemey P, Jiang X, Lam TT, Perry BW, Castoe TA, Rambaut A, Robertson DL. 2020. Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic. Nat Microbiol 5:1408–1417. [https://doi.org/10.1038/s41564-020-0771-4](https://doi.org/10.1038/s41564-020-0771-4).
    
    

3.  3.Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brünink S, Schneider J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B, van den Brink S, Wijsman L, Goderski G, Romette J, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C, Koopmans MP, Drosten C. 2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 25:[https://dx.doi.org/10.2807%2F1560-7917.ES.2020.25.3.2000045](https://dx.doi.org/10.2807%2F1560-7917.ES.2020.25.3.2000045).
    
    

4.  4.Gaunt ER, Hardie A, Claas ECJ, Simmonds P, Templeton KE. 2010. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. J Clin Microbiol 48:2940–2947. [https://doi.org/10.1128/jcm.00636-10](https://doi.org/10.1128/jcm.00636-10).
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiamNtIjtzOjU6InJlc2lkIjtzOjk6IjQ4LzgvMjk0MCI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIxLzAyLzExLzIwMjEuMDIuMDguMjEyNTAwODYuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

5.  5.Prill MM, Iwane MK, Edwards KM, Williams JV, Weinberg GA, Staat MA, Willby MJ, Talbot HK, Hall CB, Szilagyi PG, Griffin MR, Curns AT, Erdman DD. 2012. Human coronavirus in young children hospitalized for acute respiratory illness and asymptomatic controls. Pediatr Infect Dis J 31:235–240. [https://doi.org/10.1097/inf.0b013e31823e07fe](https://doi.org/10.1097/inf.0b013e31823e07fe).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/INF.0b013e31823e07fe&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22094637&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F02%2F11%2F2021.02.08.21250086.atom) 

6.  6.Rhedin S, Lindstrand A, Rotzén-Östlund M, Tolfvenstam T, Ohrmalm L, Rinder MR, Zweygberg-Wirgart B, Ortqvist A, Henriques-Normark B, Broliden K, Naucler P. 2014. Clinical utility of PCR for common viruses in acute respiratory illness. Pediatrics 133:538. [https://doi.org/10.1542/peds.2013-3042](https://doi.org/10.1542/peds.2013-3042).
    
    

7.  7.Rhedin S, Lindstrand A, Hjelmgren A, Ryd-Rinder M, Öhrmalm L, Tolfvenstam T, Örtqvist Å, Rotzén-Östlund M, Zweygberg-Wirgart B, Henriques-Normark B, Broliden K, Naucler P. 2015. Respiratory viruses associated with community-acquired pneumonia in children: matched case-control study. Thorax 70:847–853. [https://doi.org/10.1136/thoraxjnl-2015-206933](https://doi.org/10.1136/thoraxjnl-2015-206933).
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6OToidGhvcmF4am5sIjtzOjU6InJlc2lkIjtzOjg6IjcwLzkvODQ3IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjEvMDIvMTEvMjAyMS4wMi4wOC4yMTI1MDA4Ni5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

8.  8.Chau NVV, Thanh Lam V, Thanh Dung N, Yen LM, Minh NNQ, Hung LM, Ngoc NM, Dung NT, Man DNH, Nguyet LA, Nhat LTH, Nhu LNT, Ny NTH, Hong NTT, Kestelyn E, Dung NTP, Xuan TC, Hien TT, Thanh Phong N, Tu TNH, Geskus RB, Thanh TT, Thanh Truong N, Binh NT, Thuong TC, Thwaites G, Tan LV. 2020. The natural history and transmission potential of asymptomatic SARS-CoV-2 infection. Clin Infect Dis 71:2679–2687. [https://doi.org/10.1093/cid/ciaa711](https://doi.org/10.1093/cid/ciaa711).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/cid/ciaa711&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32497212&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F02%2F11%2F2021.02.08.21250086.atom) 

9.  9.Kissler SM, Fauver JR, Mack C, Tai C, Shiue KY, Kalinich CC, Jednak S, Ott IM, Vogels CBF, Wohlgemuth J, Weisberger J, DiFiori J, J. Anderson D, Mancell J, Ho DD, Grubaugh ND, Grad YH. 2020. Viral dynamics of SARS-CoV-2 infection and the predictive value of repeat testing. medRxiv [https://doi.org/10.1101/2020.10.21.20217042](https://doi.org/10.1101/2020.10.21.20217042).
    
    

10. 10.Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, Taylor J, Spicer K, Bardossy AC, Oakley LP, Tanwar S, Dyal JW, Harney J, Chisty Z, Bell JM, Methner M, Paul P, Carlson CM, McLaughlin HP, Thornburg N, Tong S, Tamin A, Tao Y, Uehara A, Harcourt J, Clark S, Brostrom-Smith C, Page LC, Kay M, Lewis J, Montgomery P, Stone ND, Clark TA, Honein MA, Duchin JS, Jernigan JA. 2020. Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. N Engl J Med 382:2081–2090. [https://doi.org/10.1056/nejmoa2008457](https://doi.org/10.1056/nejmoa2008457).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2008457&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F02%2F11%2F2021.02.08.21250086.atom) 

11. 11.Bullard J, Dust K, Funk D, Strong JE, Alexander D, Garnett L, Boodman C, Bello A, Hedley A, Schiffman Z, Doan K, Bastien N, Li Y, Van Caeseele PG, Poliquin G. 2020. Predicting infectious SARS-CoV-2 from diagnostic samples. Clin Infect Dis 71:2663–2666. [https://doi.org/10.1093/cid/ciaa638](https://doi.org/10.1093/cid/ciaa638).
    
    

12. 12.La Scola B, Le Bideau M, Andreani J, Hoang VT, Grimaldier C, Colson P, Gautret P, Raoult D. 2020. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur J Clin Microbiol Infect Dis 39:1059–1061. [https://doi.org/10.1007/s10096-020-03913-9](https://doi.org/10.1007/s10096-020-03913-9).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/sl0096-020-03913-9&link_type=DOI) 

13. 13.Pekosz A, Cooper CK, Parvu V, Li M, Andrews JC, Manabe YC, Kodsi S, Leitch J, Gary DS, Roger-Dalbert C. 2020. Antigen-based testing but not real-time PCR correlates with SARS-CoV-2 virus culture. Clin Infect Dis ciaa1706. [https://doi.org/10.1093/cid/ciaa1706](https://doi.org/10.1093/cid/ciaa1706).
    
    

14. 14.Singanayagam A, Patel M, Charlett A, Lopez Bernal J, Saliba V, Ellis J, Ladhani S, Zambon M, Gopal R. 2020. Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. Euro Surveill 25:[https://doi.org/10.2807/1560-7917.es.2020.25.32.2001483](https://doi.org/10.2807/1560-7917.es.2020.25.32.2001483).
    
    

15. 15.Cao S, Gan Y, Wang C, Bachmann M, Wei S, Gong J, Huang Y, Wang T, Li L, Lu K, Jiang H, Gong Y, Xu H, Shen X, Tian Q, Lv C, Song F, Yin X, Lu Z. 2020. Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China. Nature Communications 11:1–7. [https://doi.org/10.1038/s41467-020-19802-w](https://doi.org/10.1038/s41467-020-19802-w).
    
    

16. 16.Jaafar R, Aherfi S, Wurtz N, Grimaldier C, Van Hoang T, Colson P, Raoult D, La Scola B. 2020. Correlation Between 3790 Quantitative Polymerase Chain Reaction–Positives Samples and Positive Cell Cultures, Including 1941 Severe Acute Respiratory Syndrome Coronavirus 2 Isolates. Clinical Infectious Diseases [https://doi.org/10.1093/cid/ciaa1491](https://doi.org/10.1093/cid/ciaa1491).
    
    

17. 17.Inagaki K, Song M, Crumpton J, DeBeauchamp J, Jeevan T, Tuomanen EI, Webby RJ, Hakim H.2016. Correlation Between the Interval of Influenza Virus Infectivity and Results of Diagnostic Assays in a Ferret Model. J Infect Dis 213:407–410. [https://doi.org/10.1093/infdis/jiv331](https://doi.org/10.1093/infdis/jiv331).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/infdis/jiv331&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=26068783&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F02%2F11%2F2021.02.08.21250086.atom) 

18. 18.Pollock AM, Lancaster J. 2020. Asymptomatic transmission of covid-19. BMJ 371:m4851:[http://dx.doi.org/10.1136/bmj.m4851](http://dx.doi.org/10.1136/bmj.m4851).
    
    [FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiRlVMTCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYm1qIjtzOjU6InJlc2lkIjtzOjE3OiIzNzEvZGVjMjFfMS9tNDg1MSI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIxLzAyLzExLzIwMjEuMDIuMDguMjEyNTAwODYuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

19. 19.Wada M, Lokugamage KG, Nakagawa K, Narayanan K, Makino S. 2018. Interplay between coronavirus, a cytoplasmic RNA virus, and nonsense-mediated mRNA decay pathway. Proc Natl Acad Sci U S A 115:E10157–E10166. [https://doi.org/10.1073/pnas.1811675115](https://doi.org/10.1073/pnas.1811675115).
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoicG5hcyI7czo1OiJyZXNpZCI7czoxMzoiMTE1LzQzL0UxMDE1NyI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIxLzAyLzExLzIwMjEuMDIuMDguMjEyNTAwODYuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

20. 20.Almazán F, Galán C, Enjuanes L. 2004. The nucleoprotein is required for efficient coronavirus genome replication. J Virol 78:12683–12688. [https://doi.org/10.1128/jvi.78.22.12683-12688.2004](https://doi.org/10.1128/jvi.78.22.12683-12688.2004).
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoianZpIjtzOjU6InJlc2lkIjtzOjExOiI3OC8yMi8xMjY4MyI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIxLzAyLzExLzIwMjEuMDIuMDguMjEyNTAwODYuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

21. 21.Zúñiga S, Cruz JLG, Sola I, Mateos-Gómez PA, Palacio L, Enjuanes L. 2010. Coronavirus nucleocapsid protein facilitates template switching and is required for efficient transcription. J Virol 84:2169–2175. [https://doi.org/10.1128/jvi.02011-09](https://doi.org/10.1128/jvi.02011-09).
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoianZpIjtzOjU6InJlc2lkIjtzOjk6Ijg0LzQvMjE2OSI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIxLzAyLzExLzIwMjEuMDIuMDguMjEyNTAwODYuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

22. 22.Alexandersen S, Chamings A, Bhatta TR. 2020. SARS-CoV-2 genomic and subgenomic RNAs in diagnostic samples are not an indicator of active replication. Nat Commun 11:6059. [https://doi.org/10.1038/s41467-020-19883-7](https://doi.org/10.1038/s41467-020-19883-7).
    
    

23. 23.Hofmann MA, Sethna PB, Brian DA. 1990. Bovine coronavirus mRNA replication continues throughout persistent infection in cell culture. J Virol 64:4108–4114. [https://doi.org/10.1128/jvi.64.9.4108-4114.1990](https://doi.org/10.1128/jvi.64.9.4108-4114.1990).
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoianZpIjtzOjU6InJlc2lkIjtzOjk6IjY0LzkvNDEwOCI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIxLzAyLzExLzIwMjEuMDIuMDguMjEyNTAwODYuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

24. 24.Wernike K, Keller M, Conraths FJ, Mettenleiter TC, Groschup MH, Beer M. 2020. Pitfalls in SARS-CoV-2 PCR diagnostics. Transbound Emerg Dis [https://doi.org/10.1111/tbed.13684](https://doi.org/10.1111/tbed.13684).
    
    

25. 25.Santarpia JL, Rivera DN, Herrera VL, Morwitzer MJ, Creager HM, Santarpia GW, Crown KK, Brett-Major DM, Schnaubelt ER, Broadhurst MJ, Lawler JV, Reid SP, Lowe JJ. 2020. Aerosol and surface contamination of SARS-CoV-2 observed in quarantine and isolation care. Sci Rep 10:12732. [https://doi.org/10.1038/s41598-020-69286-3](https://doi.org/10.1038/s41598-020-69286-3).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41598-020-69286-3&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32728118&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F02%2F11%2F2021.02.08.21250086.atom) 

26. 26.Zhou J, Otter JA, Price JR, Cimpeanu C, Garcia DM, Kinross J, Boshier PR, Mason S, Bolt F, Holmes AH, Barclay WS. 2020. Investigating SARS-CoV-2 surface and air contamination in an acute healthcare setting during the peak of the COVID-19 pandemic in London. Clin Infect Dis [https://doi.org/10.1093/cid/ciaa905](https://doi.org/10.1093/cid/ciaa905).
    
    

27. 27.Curran T, McCaughey C, Ellis J, Mitchell SJ, Feeney SA, Watt AP, Mitchell F, Fairley D, Crawford L, McKenna J, Coyle PV. 2012. False-positive PCR results linked to administration of seasonal influenza vaccine. J Med Microbiol 61:332–338. [https://doi.org/10.1099/jmm.0.036178-0](https://doi.org/10.1099/jmm.0.036178-0).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1099/jmm.0.036178-0&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22096134&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F02%2F11%2F2021.02.08.21250086.atom) 

28. 28.Surkova E, Nikolayevskyy V, Drobniewski F. 2020. False-positive COVID-19 results: hidden problems and costs. The lancet respiratory medicine 8:1167–1168. [http://dx.doi.org/10.1016/S2213-2600(20)30453-7](http://dx.doi.org/10.1016/S2213-2600(20)30453-7).
    
    

29. 29.Mina MJ, Andersen KG. 2020. COVID-19 testing: One size does not fit all. Science 371:126–127. [https://doi.org/10.1126/science.abe9187](https://doi.org/10.1126/science.abe9187).
    
    

30. 30.Bruning AHL, Aatola H, Toivola H, Ikonen N, Savolainen-Kopra C, Blomqvist S, Pajkrt D, Wolthers KC, Koskinen JO. 2018. Rapid detection and monitoring of human coronavirus infections. New Microbes New Infect 24:52–55. [https://doi.org/10.1016/j.nmni.2018.04.007](https://doi.org/10.1016/j.nmni.2018.04.007).
    
    

31. 31.Vandroux D, Allou N, Jabot J, Li Pat Yuen G, Brottet E, Roquebert B, Martinet O. 2018. Intensive care admission for Coronavirus OC43 respiratory tract infections. Med Mal Infect 48:141–144. [https://doi.org/10.1016/j.medmal.2018.01.001](https://doi.org/10.1016/j.medmal.2018.01.001).
    
    

32. 32.Hänninen P, Soini A, Meltola N, Soini J, Soukka J, Soini E. 2000. A new microvolume technique for bioaffinity assays using two-photon excitation. Nat Biotechnol 18:548–550. [https://doi.org/10.1038/75421](https://doi.org/10.1038/75421).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/75421&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=10802624&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F02%2F11%2F2021.02.08.21250086.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000087017500030&link_type=ISI) 

33. 33.Koskinen JO, Vainionpää R, Meltola NJ, Soukka J, Hänninen PE, Soini AE. 2007. Rapid method for detection of influenza a and B virus antigens by use of a two-photon excitation assay technique and dry-chemistry reagents. J Clin Microbiol 45:3581–3588. [https://doi.org/10.1128/JCM.00128-07](https://doi.org/10.1128/JCM.00128-07).
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiamNtIjtzOjU6InJlc2lkIjtzOjEwOiI0NS8xMS8zNTgxIjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjEvMDIvMTEvMjAyMS4wMi4wOC4yMTI1MDA4Ni5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

34. 34.Gunell M, Antikainen P, Porjo N, Irjala K, Vakkila J, Hotakainen K, Kaukoranta SS, Hirvonen JJ, Saha K, Manninen R, Forsblom B, Rantakokko-Jalava K, Peltola V, Koskinen JO, Huovinen P. 2016. Comprehensive real-time epidemiological data from respiratory infections in Finland between 2010 and 2014 obtained from an automated and multianalyte mariPOC® respiratory pathogen test. Eur J Clin Microbiol Infect Dis 35:405–413. [https://doi.org/10.1007/s10096-015-2553-0](https://doi.org/10.1007/s10096-015-2553-0).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s10096-015-2553-0&link_type=DOI) 

35. 35.Rusanen J, Kareinen L, Szirovicza L, Uĝurlu H, Levanov L, Jääskeläinen A, Ahava M, Kurkela S, Saksela K, Hedman K, Vapalahti O, Hepojoki J. 2020. A generic, scalable, and rapid TR-FRET –based assay for SARS-CoV-2 antigen detection. medRxiv [https://doi.org/10.1101/2020.12.07.20245167](https://doi.org/10.1101/2020.12.07.20245167).
    
    

36. 36.Vakkila J, Koskinen JO, Brandt A, Muotiala A, Liukko V, Soittu S, Meriluoto S, Vesalainen M, Huovinen P, Irjala K. 2015. Detection of Group A Streptococcus from Pharyngeal Swab Samples by Bacterial Culture Is Challenged by a Novel mariPOC Point-of-Care Test. Journal of Clinical Microbiology 53:2079–2083. [https://doi.org/10.1128/jcm.00018-15](https://doi.org/10.1128/jcm.00018-15).
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiamNtIjtzOjU6InJlc2lkIjtzOjk6IjUzLzcvMjA3OSI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIxLzAyLzExLzIwMjEuMDIuMDguMjEyNTAwODYuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

37. 37.Liotti FM, Menchinelli G, Marchetti S, Morandotti GA, Sanguinetti M, Posteraro B, Cattani P. 2020. Evaluation of three commercial assays for SARS-CoV-2 molecular detection in upper respiratory tract samples. European Journal of Clinical Microbiology & Infectious Diseases: Official Publication of the European Society of Clinical Microbiology 40:269–277. [https://doi.org/10.1007/s10096-020-04025-0](https://doi.org/10.1007/s10096-020-04025-0).
    
    

38. 38.Jokela P, Jääskeläinen AE, Jarva H, Holma T, Ahava MJ, Mannonen L, Lappalainen M, Kurkela S, Loginov R. 2020. SARS-CoV-2 sample-to-answer nucleic acid testing in a tertiary care emergency department: evaluation and utility. J Clin Virol 131:104614. [https://doi.org/10.1016/j.jcv.2020.104614](https://doi.org/10.1016/j.jcv.2020.104614).
    
    

39. 39.Wulff NH, Tzatzaris M, Young PJ. 2012. Monte Carlo simulation of the Spearman-Kaerber TCID50. J Clin Bioinforma 2:5. [https://doi.org/10.1186/2043-9113-2-5](https://doi.org/10.1186/2043-9113-2-5).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/2043-9113-2-5&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22330733&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F02%2F11%2F2021.02.08.21250086.atom) 

40. 40.Guglielmi G. 2020. Fast coronavirus tests: what they can and can’t do. Nature 585:496–498. [https://doi.org/10.1038/d41586-020-02661-2](https://doi.org/10.1038/d41586-020-02661-2).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/d41586-020-02661-2&link_type=DOI) 

41. 41.Larremore DB, Wilder B, Lester E, Shehata S, Burke JM, Hay JA, Tambe M, Mina MJ, Parker R. 2020. Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening. Sci Adv 7:eabd5393. [https://doi.org/10.1126/sciadv.abd5393](https://doi.org/10.1126/sciadv.abd5393).
    
    [FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6MzoiUERGIjtzOjExOiJqb3VybmFsQ29kZSI7czo4OiJhZHZhbmNlcyI7czo1OiJyZXNpZCI7czoxMjoiNy8xL2VhYmQ1MzkzIjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjEvMDIvMTEvMjAyMS4wMi4wOC4yMTI1MDA4Ni5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

42. 42.Mina MJ, Parker R, Larremore DB. 2020. Rethinking Covid-19 Test Sensitivity - A Strategy for Containment. N Engl J Med 383:e120. [https://doi.org/10.1056/nejmp2025631](https://doi.org/10.1056/nejmp2025631).
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F02%2F11%2F2021.02.08.21250086.atom) 

43. 43.He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, Lau YC, Wong JY, Guan Y, Tan X, Mo X, Chen Y, Liao B, Chen W, Hu F, Zhang Q, Zhong M, Wu Y, Zhao L, Zhang F, Cowling BJ, Li F, Leung GM. 2020. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med 26:672–675. [https://doi.org/10.1038/s41591-020-0869-5](https://doi.org/10.1038/s41591-020-0869-5).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.7326/M20-3012&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F02%2F11%2F2021.02.08.21250086.atom) 

44. 44.Koskinen JM, Soukka JM, Meltola NJ, Koskinen JO. 2018. Microbial identification from feces and urine in one step by two-photon excitation assay technique. Journal of Immunological Methods 460:113–118. [https://doi.org/10.1016/j.jim.2018.06.017](https://doi.org/10.1016/j.jim.2018.06.017).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jim.2018.06.017&link_type=DOI) 

45. 45.Albert E, Torres I, Bueno F, Huntley D, Molla E, Fernández-Fuentes MÁ, MartÍnez M, Poujois S, Forqué L, Valdivia A,  Solano de la Asunción, Carlos, Ferrer J, Colomina J, Navarro D. 2020. Field evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres. Clin Microbiol Infect [https://doi.org/10.1016/j.cmi.2020.11.004](https://doi.org/10.1016/j.cmi.2020.11.004).
    
    

46. 46.Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, Niemeyer D, Jones TC, Vollmar P, Rothe C, Hoelscher M, Bleicker T, Brünink S, Schneider J, Ehmann R, Zwirglmaier K, Drosten C, Wendtner C. 2020. Virological assessment of hospitalized patients with COVID-2019. Nature 581:465–469. [https://doi.org/10.1038/s41586-020-2196-x](https://doi.org/10.1038/s41586-020-2196-x).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41586-020-2196-x&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F02%2F11%2F2021.02.08.21250086.atom) 

47. 47.Sohn Y, Jeong SJ, Chung WS, Hyun JH, Baek YJ, Cho Y, Kim JH, Ahn JY, Choi JY, Yeom J. 2020. Assessing Viral Shedding and Infectivity of Asymptomatic or Mildly Symptomatic Patients with COVID-19 in a Later Phase. J Clin Med 9:2924. [https://doi.org/10.3390/jcm9092924](https://doi.org/10.3390/jcm9092924).
    
    

48. 48.Basile K, McPhie K, Carter I, Alderson S, Rahman H, Donovan L, Kumar S, Tran T, Ko D, Sivaruban T, Ngo C, Toi C, O’Sullivan MV, Sintchenko V,  Chen SC-, Maddocks S, Dwyer DE, Kok J. 2020. Cell-based culture of SARS-CoV-2 informs infectivity and safe de-isolation assessments during COVID-19. Clin Infect Dis ciaa1579. [https://doi.org/10.1093/cid/ciaa1579](https://doi.org/10.1093/cid/ciaa1579).
    
    

49. 49.Dinnes J, Deeks JJ, Adriano A, Berhane S, Davenport C, Dittrich S, Emperador D, Takwoingi Y, Cunningham J, Beese S, Dretzke J, Ferrante di Ruffano L, Harris IM, Price MJ, Taylor-Phillips S, Hooft L, Leeflang MM, Spijker R, Van den Bruel A. 2020. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev 8:CD013705. [https://doi.org/10.1002/14651858.cd013705](https://doi.org/10.1002/14651858.cd013705).
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32845525&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F02%2F11%2F2021.02.08.21250086.atom)